Valaciclovir for herpesvirus treatment and prevention in Janus kinase inhibitor‐treated patients: an Australian experience and registry call
The data that supports the findings of this study are available in the supplementary material of this article. Supplementary Table S1. High vs Standard/Other Dosing of Janus kinase Inhibitors. Derived from the “Monthly Index of Medical Specialties”, accessed November 2024. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Authors
- Rohan A. Elliott (ORCID: https://orcid.org/0000-0002-7750-9724)
- Elise Mitri (ORCID: https://orcid.org/0000-0002-1250-2847)
- Stephen Cheung
- Olivia Catherine Smibert (ORCID: https://orcid.org/0000-0003-1232-5884)
- Karen Urbancic (ORCID: https://orcid.org/0000-0002-9275-578X)
- A Batrouney
- S Motaganahalli (ORCID: https://orcid.org/0000-0002-6739-0424)
- Jason A. Trubiano (ORCID: https://orcid.org/0000-0002-5111-6367)
- Lionel Schachna
- Gordon Reynolds
- Zoe Kantanis
Institutions
- Peter MacCallum Cancer Centre (AU)
- Peter Doherty Institute (AU)
- Austin Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1111/imj.70374
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00